Characterization of novel CD55 isoforms expression in normal and neoplastic tissues

Tissue Antigens

Volumn 82, Issue 1, 2013, Pages 26-34

  Vainer, E D ^a   Meir, K ^a   Furman, M ^a   Semenenko, I ^a   Konikoff, F ^b   Vainer, G W ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cancer; CD55; CD55 intron 7; Decay accelerating factor; Splice variants

Indexed keywords

DECAY ACCELERATING FACTOR; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER TISSUE; CHO CELL; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTRON; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD55; CELL LINE, TUMOR; CHO CELLS; COLORECTAL NEOPLASMS; CRICETINAE; CRICETULUS; CROSS REACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84879800655     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12138     Document Type: Article

References (19)

1. Lanza G, Matteuzzi M, Gafa R et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998: 79: 390-5.
2. Merkel S, Wein A, Gunther K et al. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001: 92: 1435-43.
3. Durrant LG, Chapman MA, Buckley DJ et al. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 2003: 52: 638-42.
4. Vollmers HP, Zimmermann U, Krenn V et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 1998: 5: 549-52.
5. Macor P, Tripodo C, Zorzet S et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007: 67: 10556-63.
6. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984: 160: 1558-78.
7. Nicholson-Weller A, Burge AJ, Fearon DT, Weller PF, Austen KF. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982: 129: 184-9.
8. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987: 165: 848-64.
9. Caras IW, Weddell GN, Williams SR. Analysis of the signal for attachment of a glycophospholipid membrane anchor. J Cell Biol 1989: 108: 1387-96.
10. Osuka F, Endo Y, Higuchi M et al. Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor. Genomics 2006: 88: 316-22.
11. Wang G, Nonaka M, He C et al. Functional differences among multiple isoforms of guinea pig decay-accelerating factor. J Immunol 1998: 160: 3014-22.
12. Spendlove I, Li L, Carmichael J, Durrant LG. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res 1999: 59: 2282-6.
13. Koretz K, Bruderlein S, Henne C, Moller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br J Cancer 1992: 66: 810-4.
14. Inoue H, Mizuno M, Uesu T, Ueki T, Tsuji T. Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer. Acta Med Okayama 1994: 48: 271-7.
15. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (Membrane Cofactor Protein), CD55 (Decay-Accelerating Factor), and CD59 (Protectin). Am J Pathol 1996: 149: 129-42.
16. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011: 10: 591-600.
17. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer 2001: 84: 80-6.
18. Site, c., http://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/systems_info&system=cromer. 2011.
19. Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 2006: 124: 119-31.